-
The adverse publicity following publications from the Women's Health Initiative was a multibillion dollar bonanza for compounding pharmacies providing postmenopausal hormones.
-
-
In this issue: The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
-
Inhaled salmeterol and fluticasone, singly or in combination, reduce the rate of decline of the FEV1 in patients with moderate-to-severe COPD.
-
CT colonographic screening of asymptomatic adults identified 90% of polyps or cancers measuring 10 mm or more.
-
Homocysteine (HCYS) has all the trappings of a first-rate cardiovascular risk factor: as strong an association with CVD endpoints as cholesterol, ease of identification, and simplicity of modulation. Trouble is, trials to date have been unable to show that reductions of homocysteine provide meaningful benefits to patients.
-
Intensive hemoglobin A1c lowering does not reduce the rate of cardiovascular death, and results in an increase in hypoglycemic events.
-
-
Lifestyle changes plus red yeast rice and fish oil resulted in similar beneficial effects on LDL cholesterol as moderate-dose statin therapy in patients meeting criteria for drug therapy for high LDL cholesterol.